JO
BSTG

John Overdeck’s Biostage, Inc. Common Stock BSTG Stock Holding History

John Overdeck’s Portfolio BSTG Stock Details BSTG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-12,233
Closed -$111K – 2476
2014
Q1 		$111K Buy
+12,233
New +$72.5K ﹤0.01% 1877

Other funds holding BSTG

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $2.02B AUM 40.6% 1-Year Est. Return
HSA
Hussman Strategic Advisors Ellicott City, Maryland $434M AUM 19.64% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

John Overdeck's BSTG Position: Q2 2014 in Review

John Overdeck sold out of Biostage, Inc. Common Stock (BSTG) in Q2 2014, closing a stake of 12,233 shares — an estimated $111K sold.

John Overdeck first reported a position in BSTG in Q1 2014 and held it in 1 quarter. The position peaked at $111K in Q1 2014. 53 funds tracked by Wall St. Rank hold BSTG as of Q2 2014.

  • John Overdeck reported no remaining Biostage, Inc. Common Stock position as of Q2 2014 after selling out during the quarter.
  • John Overdeck sold 12,233 Biostage, Inc. Common Stock shares in Q2 2014, an estimated $111K.
  • John Overdeck first reported a position in Biostage, Inc. Common Stock in Q1 2014 and held it in 1 quarter.
  • John Overdeck's Biostage, Inc. Common Stock position peaked at $111K in Q1 2014.
  • 53 funds tracked by Wall St. Rank held Biostage, Inc. Common Stock as of Q2 2014.

Based on Two Sigma Investments's 13F filing for Q2 2014, filed 14 Aug 2014.